Sarepta Therapeutics, Inc. $SRPT Holdings Raised by Sigma Planning Corp

Sigma Planning Corp lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 163.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,545 shares of the biotechnology company’s stock after acquiring an additional 36,299 shares during the period. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $1,260,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth about $33,000. Allworth Financial LP lifted its position in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,256 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Barclays initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective for the company. Royal Bank Of Canada lifted their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Wells Fargo & Company lowered their target price on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Wedbush increased their price target on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 26th. Finally, Loop Capital set a $25.00 price target on Sarepta Therapeutics in a report on Tuesday, March 3rd. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $32.63.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the sale, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $21.49 on Monday. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. The company’s 50-day moving average price is $19.58 and its 200 day moving average price is $20.32. The company has a market cap of $2.27 billion, a PE ratio of -2.55, a P/E/G ratio of 0.33 and a beta of 0.26. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $64.80.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. Sarepta Therapeutics’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.90 EPS. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.89 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.